Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society

Q: What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Physicians' perception of renal denervation for resistant hypertension (n=206). Intervention: Renal denervation (RDN) as a treatment for resistant hypertension. Primary outcome: Awareness of RDN.

Nicolás Renna; Roberto Parodi; E Ylarri; G. Lavenia; María José Solís Marín; Mauro Ruise; R Sánchez; Daniela Cianfagna; G Botvinik; Paola Rumi; V Ferreti

doi:10.1016/j.hipert.2024.10.003

December 6, 2024Hipertensión y Riesgo Vascular

Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society

View at Publisher

Ask AI

Bookmark

Share

Key result

Specialized Argentine physicians demonstrated high awareness of renal denervation, but only 60% believed in its safety for treating resistant hypertension.

Why the study?

The study investigated the perceptions and knowledge of specialized Argentine physicians regarding renal denervation as a treatment for resistant hypertension.

Key Points

To evaluate the awareness, perceptions, and knowledge of specialized physicians regarding renal denervation as a therapeutic approach for resistant hypertension.
Surveyed 206 specialized physicians, predominantly cardiologists and internists, regarding their knowledge and opinions of renal denervation.
Analyzed responses using descriptive statistics and evaluated associations between procedural awareness, efficacy, and safety using Spearman's Rho correlation.
Overall, 83% of the surveyed physician respondents reported awareness of renal denervation.
Regarding procedural safety, 60% of physicians believed renal denervation is safe, 33.2% were uncertain, and 6.8% regarded it as unsafe.
Significant correlations were identified between physicians' awareness of renal denervation and their perceptions of its clinical efficacy and safety.

Study Design

Type

Cross-Sectional (n=206)

Structured PICO

P

Population

206 specialized Argentine physicians, mainly cardiologists and internists, surveyed to assess their awareness and perceptions of renal denervation.

E

Exposure

Survey assessing awareness and perceptions of renal denervation (RDN) for resistant hypertension

O

Outcome

Awareness and perceptions of RDN safety and efficacy

There is a gap between knowledge and confidence in the safety of renal denervation among specialized Argentine physicians, highlighting the need for targeted educational initiatives.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Low belief in renal denervation safety may limit adoption; leaves open whether education improves specialist confidence in resistant hypertension.

Abstract

INTRODUCTION: This study investigates the perceptions and knowledge of specialized Argentine physicians regarding renal denervation (RDN) as a treatment for resistant hypertension (R-HT). METHOD: A survey was conducted among 206 physicians, mainly cardiologists and internists, to assess their awareness and perceptions of RDN. Data were analyzed using descriptive statistics and Spearman's Rho correlation. RESULTS: The survey revealed that 83% of the responders are aware of RDN. Despite this high awareness, only 60% believe in its safety, while 33.2% are uncertain, and 6.8% consider it unsafe. Significant correlations were found between the awareness of RDN and perceptions of its efficacy and safety. CONCLUSIONS: The study highlights a gap between knowledge and confidence in RDN among specialized Argentine physicians. Continuous education and shared decision-making are crucial to improve the adoption of RDN in clinical practice. Long-term safety and efficacy data support RDN as a valuable tool for managing R-HT. Addressing safety concerns through targeted educational initiatives is essential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Renna et al. (2024) conducted a cross-sectional in Physicians' perception of renal denervation for resistant hypertension (n=206). Renal denervation (RDN) as a treatment for resistant hypertension was evaluated on Awareness of RDN. Specialized Argentine physicians demonstrated high awareness of renal denervation, but only 60% believed in its safety for treating resistant hypertension.

synapsesocial.com/papers/6a9ac9490b4fe24714b47330 https://doi.org/10.1016/j.hipert.2024.10.003

View at Publisher

Ask AI

Bookmark

Share

Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading